Literature DB >> 8392414

Bubble-induced aggregation of platelets: effects of gas species, proteins, and decompression.

T Thorsen1, H Klausen, R T Lie, H Holmsen.   

Abstract

We show that bubbles containing different gases (N2, He, Ne, Ar, or an O2-CO2-N2 mixture) are equally potent platelet agonists. The synergistic effect of different platelet antagonists does not seem to be affected by the type of gas in the bubbles. In contrast to aggregation in platelet-rich plasma (PRP), bubbles cause only a weak response in gel-filtered platelets (GFP), i.e., comparison of aggregation in protein-rich and protein-poor platelet suspensions may shed light on the role of different plasma proteins. Extracellular fibrinogen promotes bubble-induced platelet aggregation similar to known physiologic agonists, whereas albumin counteracts this aggregation. Bubble-induced aggregation is inhibited in GFP-fibrinogen by 2-deoxy-D-glucose plus antimycin A, suggesting dependency on ATP generation in the platelets and evidence for direct exposure of the "cryptic" fibrinogen receptor by bubbles. Hyperbaric compression and subsequent rapid, inadequate decompression of PRP caused little change in the aggregation response to gas bubbles and epinephrine at 1 bar, but reduced the response to ADP. Bubbles tended not to form before the surface film was broken. Pressure-induced aggregation was apparently metabolically active and not due to passive agglutination; electron microscopic studies and PRP with added glutaraldehyde did not show platelet activation, clumping, or reduced platelet count. In contrast to aggregation caused by pressure, bubble-induced aggregation in PRP at 1 bar (after treatment in the pressure chamber) was nearly completely inhibited by theophylline, a phosphodiesterase inhibitor that increases intracellular platelet cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392414

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  8 in total

Review 1.  In Vitro models for thrombogenicity testing of blood-recirculating medical devices.

Authors:  Deepika N Sarode; Shuvo Roy
Journal:  Expert Rev Med Devices       Date:  2019-06-10       Impact factor: 3.166

2.  The use of the ex vivo Chandler Loop Apparatus to assess the biocompatibility of modified polymeric blood conduits.

Authors:  Joshua B Slee; Ivan S Alferiev; Robert J Levy; Stanley J Stachelek
Journal:  J Vis Exp       Date:  2014-08-20       Impact factor: 1.355

Review 3.  Endothelial Glycocalyx and Cardiopulmonary Bypass.

Authors:  Gerard J Myers; Julie Wegner
Journal:  J Extra Corpor Technol       Date:  2017-09

4.  Comparison of modified chandler, roller pump, and ball valve circulation models for in vitro testing in high blood flow conditions: application in thrombogenicity testing of different materials for vascular applications.

Authors:  Wim van Oeveren; Ignace F Tielliu; Jurgen de Hart
Journal:  Int J Biomater       Date:  2012-05-09

5.  Bubbles in live-stranded dolphins.

Authors:  S Dennison; M J Moore; A Fahlman; K Moore; S Sharp; C T Harry; J Hoppe; M Niemeyer; B Lentell; R S Wells
Journal:  Proc Biol Sci       Date:  2011-10-12       Impact factor: 5.349

Review 6.  Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility.

Authors:  Marbod Weber; Heidrun Steinle; Sonia Golombek; Ludmilla Hann; Christian Schlensak; Hans P Wendel; Meltem Avci-Adali
Journal:  Front Bioeng Biotechnol       Date:  2018-07-16

Review 7.  Obstacles in haemocompatibility testing.

Authors:  W van Oeveren
Journal:  Scientifica (Cairo)       Date:  2013-05-07

8.  Pre-dive Whole-Body Vibration Better Reduces Decompression-Induced Vascular Gas Emboli than Oxygenation or a Combination of Both.

Authors:  Costantino Balestra; Sigrid Theunissen; Virginie Papadopoulou; Cedric Le Mener; Peter Germonpré; François Guerrero; Pierre Lafère
Journal:  Front Physiol       Date:  2016-11-30       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.